Précédent|Prochain

Étude rétrospective de l'application par le professeur Wang Zulong du traitement traditionnel de purification et d'accumulation d'énergie dans 132 cas d'induration du pénis

  • role： First author第一作者
  • Affiliation：

    The First Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 450046，China

    The First Clinical Medical College of Henan University of Chinese Medicine，Zhengzhou 450000，China

  • Email：Liyuanyuan123@163.com
  • Introduction：李圆圆，在读硕士，从事中医药防治生殖与男科疾病专业研究，E-mail：Liyuanyuan123@163.com
LI Yuanyuan12,  
  • role： Corresponding author通信作者
  • Affiliation：

    The First Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 450046，China

  • Email：Wangzulong123@126.com
  • Introduction：王祖龙，硕士，教授，从事中医药防治生殖与男科疾病专业研究，E-mail：Wangzulong123@126.com
WANG Zulong1*

résumé

Cette étude vise à passer en revue et à analyser 132 cas d'induration du pénis traités avec succès par le professeur Wang Zulong utilisant le traitement traditionnel de purification et d'accumulation d'énergie. L'étude vise également à évaluer l'efficacité générale du traitement traditionnel et les améliorations significatives de la taille de l'induration après 12 semaines de traitement, de l'augmentation de l'élasticité de l'érection, de l'angle de courbure du pénis, ainsi que des améliorations significatives de l'intensité de la douleur pendant l'érection.

mots-clés

Traitement traditionnel de purification et d'accumulation d'énergie; Induration du pénis; Kyste pénien; Étude rétrospective

References

  1. 1.
    JAROW J P，LOWE F C.Penile trauma：An etiologic factor in Peyronie's disease and erectile dysfunction［J］.J Urol，1997，158（4）：1388-1390.
  2. 2.
    STUNTZ M，PERLAKY A，DES VIGNES F，et al.The prevalence of Peyronie's disease in the united states：A population-based study［J］.PLoS One，2016，11（2）：e0150157.
  3. 3.
    MULHALL，J P，CREECH，S D，BOORJIAN S A，et al.Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening［J］.J Urol，2004，171（6 Pt 1）：2350-2353.
  4. 4.
    DI MAIDA F，CITO G，LAMBERTINI L，et al.The natural history of Peyronie's disease［J］.World J Mens Health，2021，39（3）：399-405.
  5. 5.
    MULHALL J P，SCHIFF J，GUHRING P.An analysis of the natural history of Peyronie's disease［J］.J Urol，2006，175（6）：2115-2118.
  6. 6.
    Guidelines for the Diagnosis and Treatment of Peyronie's Disease of the Andrology Branch of the Chinese Medical Association.Guidelines for the diagnosis and treatment of Peyronie's disease［J］.Natl J Androl，2022，28（3）：262-272.
  7. 7.
    KADIOGLU A，OKTAR T，KANDIRALI E，et al.Incidentally diagnosed Peyronie's disease in men presenting with erectile dysfunction［J］.Int J Impot Res，2004，16（6）：540-543.
  8. 8.
    GELBARD M K，DOREY F，JAMES K.The natural history of Peyronie's disease［J］.J Urol，1990，144（6）：1376-1379.
  9. 9.
    WEIDNER W，HAUCK E W，SCHNITKER J，et al.Potassium paraaminobenzoate（POTABA） in the treatment of Peyronie's disease：A prospective，placebo-controlled，randomized study［J］.Eur Urol，2005，47（4）：530-535.
  10. 10.
    TELOKEN C，RHODEN E L，GRAZZIOTIN T M，et al.Tamoxifen versus placebo in the treatment of Peyronie's disease［J］.J Urol，1999，162（6）：2003-2005.
  11. 11.
    JIANG Q，YIN X，LILL M A，et al.Long-chain carboxychromanols，metabolites of vitamin E，are potent inhibitors of cyclooxygenases［J］.Proc Natl Acad Sci U S A，2008，105（51）：20464-20469.
  12. 12.
    XU C L，SONG T，LU M J，et al.Expert consensus on Peyronie's disease surgery［J］.Chin J Androl，2024，38（5）：13-21.
  13. 13.
    NEHRA A，ALTEROWITZ R，CULKIN D J，et al.Peyronie's disease：AUA guideline［J］.J Urol，2015，194（3）：745-753.
  14. 14.
    QIN G Z.Andrology of traditional Chinese medicine［M］.Beijing：Science Press，2022：224-228.
  15. 15.
    WIKSTRÖM L，ERIKSSON K，FRIDLUND B，et al.The clinical applicability of a daily summary of patients' self-reported postoperative pain-A repeated measure analysis［J］.J Clin Nurs，2017，26（23/24）：4675-4684.
  16. 16.
    LI D，ZHOU Z G，QU F.Clinical observation on the treatment of renal insufficiency syndrome in vascular dementia by tonifying kidney and filling sperm［J］.Intern Med J Pract Tradit Chin Med Sci，2011，25（11）：71-73.
  17. 17.
    SCHWARZER U，SOMMER F，KLOTZ T，et al.The prevalence of Peyronie's disease：Results of a large survey［J］.BJU Int，2001，88（7）：727-730.
  18. 18.
    BIAS W B，NYBERG L M，HOCHBERG M C，et al.Peyronie's disease：A newly recognized autosomal-dominant trait［J］.Am J Med Genet，1982，12（2）：227-235.
  19. 19.
    KENDIRCI M，TROST L，SIKKA S C，et al.Diabetes mellitus is associated with severe Peyronie's disease［J］.BJU Int，2007，99（2）：383-386.
  20. 20.
    ADITYA I，GROBER E D，KRAKOWSKY Y.Peyronie's disease and testosterone deficiency：Is there a link？［J］.World J Urol，2019，37（6）：1035-1041.
  21. 21.
    REDDY A G，DAI M C，SONG J J，et al.Peyronie's disease：An outcomes-based guide to non-surgical and novel treatment modalities［J］.Res Rep Urol，2023，15：55-67.
  22. 22.
    GONZALEZ-CADAVID N F，RAJFER J.Experimental models of Peyronie's disease.Implications for new therapies［J］.J Sex Med，2008，6（2）：303-313.
  23. 23.
    GELBARD M K，ROSENBLOOM J.Fibroproliferative disorders and diabetes：Understanding the pathophysiologic relationship between Peyronie's disease，Dupuytren disease and diabetes［J］.Endocrinol Diabetes Metab，2021，4（2）：e00195.
  24. 24.
    EL-SAKKA A I，TAYEB K A.Vascular impairment of erection in patients with diabetes and Peyronie's disease：Is that accumulative？［J］.J Sex Med，2009，6（6）：1736-1742.
  25. 25.
    CASTELA Â，COSTA C.Molecular mechanisms associated with diabetic endothelial-erectile dysfunction［J］.Nat Rev Urol，2016，13（5）：266-274.
  26. 26.
    CROCETTO，F，IMBIMBO，C，BARONE，B，et al.Which inflammatory marker，between systemic immune-inflammation index and neutrophil to eosinophil ratio，is associated with Peyronie's disease and are there any implications for a better understanding of its mechanisms？［J］.Basic Clin Androl，2023，33（1）：38.
  27. 27.
    MILENKOVIC U，ILG M M，CELLEK S，et al.Pathophysiology and future therapeutic perspectives for resolving fibrosis in Peyronie's disease［J］.Sex Med Rev，2019，7（4）：679-689.
  28. 28.
    HAAG S M，HAUCK E W，EICKELBERG O，et al.Investigation of the antifibrotic effect of IFN-gamma on fibroblasts in a cell culture model of Peyronie's disease［J］.Eur Urol，2008，53（2）：425-430.
  29. 29.
    EL-SAKKA A I，HASSOBA H M，CHUI R M，et al.An animal model of Peyronie's-like condition associated with an increase of transforming growth factor beta mRNA and protein expression［J］.J Urol，1997，158（6）：2284-2290.
  30. 30.
    HAN Q，LIU D C，WANG R Y，et al.A retrospective study of 63 cases of penile cavernous durronie disease treated by a three-step method of dispersing knots［J］.Beijing J Tradit Chin Med，2021，40（6）：652-654.
  31. 31.
    HUO D Z.Shugan Hua Yu Sanjie decoction in the treatment of Peyronie's disease［J］.Shandong J Tradit Chin Med，2009，28（8）：578.
  32. 32.
    BAI Z S.18 cases of Peyronie's disease treated with Ju He pills［J］.Hebei J Tradit Chin Med，2004（6）：416.
  33. 33.
    WANG G J，BI X T，ZHANG T Y，et al.Clinical significance of "blood stasis" theory in the treatment of andrology diseases［J］.J Yunnan Univ Chin Med，2023，46（6）：34-37.
  34. 34.
    LIU Q，CAO J G，WEI W Y，et al.Discuss the treatment of peyronie disease by "warming Yang and clearing colla-terals" based on collateral disease theory［J］.J Hubei Univ Chin Med，2023，25（3）：50-53.
  35. 35.
    WANG S Q，ZHANG Q，CHEN R B，et al."Fu Zheng Concept and Its Seven Methods" based on "Xie Zheng Sheng Shuai" theory in traditional Chinese medicine［J］.J Tradit Chin Med，2024，39（9）：1820-1826.
  36. 36.
    YE Y X，CHEN D M，JIA L Q，et al.Research progress on the antitumor pharmacological mechanism and clinical application of Astragalus membranaceus［J］.World Chin Med，2023，18（11）：1615-1620.
  37. 37.
    CHEN H J，LIU W，LI X Y，et al.Analysis of blood components of tangerine peel based on sequential metabolism and UPLC-HRMS［J］.Chin J Exp Tradit Med Form，2023，29（9）：179-187.
  38. 38.
    CHEN Z，LIU G Y，XIE W Y，et al.Exploring the mechanism of action of Erchen Tang Jiawei on COPD inflammation based on TNF-α/TNFR1/RIPKs pathway［J］.Chin J Exp Tradit Med Form，2024，30（9）：40-47.
  39. 39.
    TRAMA F，RICCARDO F，RUFFO A，et al.Elastosonographic changes in patients with Peyronie's disease，before and after treatment with a compound based on ecklonia bicyclis，tribulus terrestris，and water-soluble chitosan［J］.Open J Urol，2018，8：77-87.
  40. 40.
    TRAMA F，ILLIANO E，IACONO F，et al.Use of penile shear wave elastosonography for the diagnosis of Peyronie's disease：A prospective case-control study［J］.Basic Clin Androl，2022，32（1）：15.

Lire l'article complet

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website